ORANGE, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), a tech-enabled Medicare Advantage company, today announced that John Kao, founder and CEO, and Thomas Freeman, chief financial officer, will participate in the BofA Securities 2023 Health Care Conference, being held in Las Vegas, Nevada, including a presentation on Tuesday, May 9, at 1:40 p.m. PDT.
A webcast and replay of the presentation will be available on Alignment’s investor relations website at https://ir.alignmenthealth.com/.
About Alignment Healthcare
Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health is a tech-enabled Medicare Advantage company that offers more than 40 benefits-rich, value-driven plans that serve 52 counties across six states. The company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA®. Based in California, the company’s mission-focused team makes high-quality, low-cost care a reality for members every day. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit www.alignmenthealth.com.
Investor Contact
Harrison Zhuo
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Maggie Habib
mPR, Inc. for Alignment Healthcare
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$10.61 |
Daily Change: | 0.34 3.31 |
Daily Volume: | 3,578,024 |
Market Cap: | US$2.030B |
November 04, 2024 October 29, 2024 October 11, 2024 August 01, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB